Delivery Order SPE2DB24D2003-SPE2DB25FXNE4
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Pioglitazone HCL 30 mg tablets (90-count units) valued at $2,474.49. This non-competitive delivery order is scheduled for completion by September 25, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award represents a firm fixed-price transaction under an existing contract vehicle, reflecting the agency's...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Pioglitazone HCL 30 mg tablets in a quantity of 500 units. This is a firm fixed-price delivery order valued at $1,502.62, with an ultimate completion date of September 23, 2025. The award was made through open competition with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major...
- The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide Pioglitazone HCL 30 mg tablets. The contract, valued at $1,186.51, has an ultimate completion date of April 3, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) awarded solely to AmerisourceBergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through...
- The Defense Logistics Agency awarded a delivery order valued at $2,226.41 to AmerisourceBergen Drug Corp for Pioglitazone HCL 30 mg tablets (90-count units) with an ultimate completion date of September 17, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a routine pharmaceutical procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Pioglitazone HCL 15 mg tablets (30-count units) with a ceiling value of $1,142.37 and a firm fixed price structure. The order is non-competitive and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The ultimate completion date is set for...
- The Defense Logistics Agency awarded a delivery order valued at $2,663.37 to AmerisourceBergen Drug Corp for the supply of Pioglitazone HCL 15 mg tablets (90-count units) on August 21, 2025, with an ultimate completion date of August 22, 2025. This is a firm fixed-price, non-set-aside contract utilizing competitively awarded delivery order procedures. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This award represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $1,642.86 to AmerisourceBergen Drug Corp for the supply of Pioglitazone HCL 45 mg tablets (90-count) on August 21, 2025, with an ultimate completion date of August 22, 2025. The contract utilizes firm fixed pricing and carries no set-aside designation, indicating it was competitively awarded. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $21,804.19 to AmerisourceBergen Drug Corp for the supply of Pioglitazone HCL 45 mg tablets (30-count units). This competitively awarded, firm fixed-price delivery order was executed on August 21, 2025, with an ultimate completion date of August 22, 2025, and represents a non-set-aside procurement. The contract will be performed at AmerisourceBergen Drug Corp's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,847.10 for Pioglitazone HCL 45 mg tablets (90-count) on September 23, 2025, with a completion date of September 24, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The award represents a continuation of pharmaceutical supply fulfillment under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical, a comprehensive $1...
- The Defense Logistics Agency awarded a $3,498.19 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Pioglitazone HCL 30 mg tablets (90-count units). This non-set-aside contract is scheduled for completion by September 10, 2025, with performance conducted at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting federal medical supply requirements...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXNE4Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of Pioglitazone HCL 30 mg tablets in quantities of 90 units. This competitively awarded, firm fixed-price delivery order is valued at $7,265.38 and is scheduled for completion by September 29, 2025. The contract carries no set-aside designation, reflecting the contractor's demonstrated capability to meet federal procurement standards through open competition. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999 and extends through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications and medical supplies to support military healthcare programs worldwide. AmerisourceBergen's federal contract portfolio demonstrates extensive experience delivering pharmaceutical products across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.3k | 9/26/25 |